Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARAND-X
2016-003741-29Phase 3Terminated
- Sponsor
- ASL Città di Torino
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of aprepitant, emtricitabine, darunavir and cobicistat in human immunodeficiency virus infection (HIV) and HIV encephalopathy (HAND) (2 arms), sponsored by ASL Città di Torino. Primary endpoint: 6-month change in global deficit score. Started Jun 2021; status: terminated.
02
Drugs
aprepitantemtricitabinedarunavircobicistat
03
Conditions
human immunodeficiency virus infection (HIV)HIV encephalopathy (HAND)
Beyond the preview
Go deeper on 2016-003741-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003741-29.